Experience

Davis Polk advised the representatives of the underwriters in connection with an approximately $963.5 million public offering of ordinary shares of Horizon Therapeutics Public Limited…

Davis Polk advised the sole bookrunning manager on an SEC-registered offering by Schlumberger Investment SA of $350 million aggregate principal amount of 2.650% senior notes due 2030. The…

Davis Polk advised the representatives of the several underwriters in connection with a debut SEC-registered bond offering by ServiceNow, Inc. of $1.5 billion aggregate principal amount of…

Davis Polk is advising StoneCo Ltd. on its agreement for STNE Participações S.A., a controlled company of Stone that holds the software investments business of the Stone group in …

Davis Polk advised Acutus Medical, Inc. on its SEC-registered initial public offering of 10,147,058 shares of common stock for an aggregate price to the public of approximately $170 million…

Davis Polk advised the underwriters on the registered offering of $700 million aggregate principal amount of 1.100% notes due 2030 and $300 million aggregate principal amount of 2.000%…

Davis Polk advised the joint book running managers in connection with the $377.3 million initial public offering of 17,968,750 shares of common stock of Oak Street Health, Inc., which…

Davis Polk advised the representatives of the several underwriters in connection with the initial public offering by Rocket Companies, Inc. of 100,000,000 shares of Rocket Companies’ Class…

Davis Polk advised Hangzhou Tigermed Consulting Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in…

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Turning Point Therapeutics, Inc. of its common stock for up to an aggregate amount of $250 million…